Результаты поиска

Ganglioside therapy in cancer molecular insights and therapeutic opportunities.

Gangliosides, a class of glycosphingolipids located on the plasma membrane of nearly all cells, play a crucial role in cell signaling and lipid raft dynamics. Their expression is notably high during embryonic development, markedly reduced in most adult tissues, but significantly elevated in various tumor tissues. This distinct expression pattern highlights gangliosides as promising therapeutic targets due to their roles in tumor progression, metastasis, and therapeutic resistance. Targeted ganglioside therapies, particularly monoclonal antibodies against GD2, have already demonstrated clinical

Совпадение в полном тексте источника
… Tivnan A Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells Oncotarget 2017 8 10 16605 16620 10.18632/oncotarget.15073 28178667 PMC5369988 …

Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study.

Introduction In India, the costs of cancer drugs are exorbitant and cause significant financial toxicity to the affected patient and their family members. Considering this, Jan Aushadhi pharmacy stores were established across the country by the government of India with the objective of providing cheap generic medicines to patients. The objective of this study was to perform a cost comparison study of generic chemotherapeutic drugs provided through Jan Aushadhi pharmacies versus their branded counterparts. This will help patients and physicians get first-hand information on the cost variation b

Совпадение в полном тексте источника
… modulators Anastrozole (nonsteroidal aromatase inhibitor) | Tab. 1 mg. 10's | 7.80 (0.10) | 57.64 (0.77) | 55.00 (0.74) | 49.84 | 47.20 | 7.39 | 7.05 | 638.97 | 605.13 Bicalutamide (antiandrogen) | Tab. 50 mg 10's | 13.70 (0.18) | 57.06 (0.77) | 51.2 (0.69) | 43.36 | 37.50 | 4.16 | 3.74 | 316.5 | 273.72 Letrozole …

Keyword Index for Volume 107

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… inulin-type fructans 1337 invasion 129, 713, 739, 1374, 1969 irinotecan 435 ITGA9 1374 K- ras 1864 KDR 1044 Ki-67 632 KRAS 340, 1997 KRAS 626 KRAS mutation testing 345 lactate dehydrogenase 422 laminin 1153 lapatinib 956, 1075 LAT1 632 late effects 1833 leg length 165 length of stay 931 letrozole …

Keyword Index for Volume 105

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… irinotecan 53, 1131, 1522 ISET 847, 1338 isoforms 854 Jagged1 1805 JAK 407 Kaposi’s sarcoma 513 Kaposi’s sarcoma-associated herpes virus 1768 Ki 67 expression 1342 Ki67 272 kidney cancer 1096, 1741, 1772 K-Ras 246 KRAS 281, 403 laminin 5- γ 2 824 lapatinib 618 LEC motility 263 let-7 296 letrozole …

Unexpected massive bleeding caused by extensive maxillary osteonecrosis in a breast cancer patient: a case report.

Diphosphonate application is routinely recommended to treat bone metastasis (BM) in cancer patients. However, the severe side effects of diphosphonate, especially after long-term use, are often overlooked by clinicians. In this article, we describe a case in which a heavily-treated breast cancer patient, suffered from massive bleeding as a result of maxillary osteonecrosis by zoledronic acid (ZA) and apatinib. In October 2018, a 48-year-old Chinese female with breast cancer presented at our department with brain metastases. The patient had experienced progression multiple times and had receive

Совпадение в полном тексте источника
… The treatment strategy was switched to a bilateral oophorectomy followed by letrozole and ZA. In February 2017, the patient experienced a second progression of pulmonary metastases. …

Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care.

BackgroundAn unmet medical need exists for many oncology patients who cannot be treated satisfactorily by available therapeutic options. Early access provision (EAP) is endorsed by competent authorities to improve patient access to innovative medicinal products (InMPs). This paper determined awareness and understanding among practicing physicians of integrated EAP protocols, and of the procedures involved in EAP applications for oncology trials prior to marketing authorization.MethodsAn on-line, fully anonymous survey reaching out to more than 3,258 physicians (including practicing oncologists

Совпадение в полном тексте источника
… with bortezomib and dexamethasone for relapsed and refractory multiple myeloma | NCT02211222 | Lenvatinib | 2/13/2015 | Expanded access program for the treatment of radioiodine-refractory differentiated thyroid cancer | NCT02142868 | Palbociclib | 2/3/2015 | Expanded access study in combination with letrozole …

The therapeutic role of γδT cells in TNBC.

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that presents significant therapeutic challenges due to the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. As a result, conventional hormonal and targeted therapies are largely ineffective, underscoring the urgent need for novel treatment strategies. γδT cells, known for their robust anti-tumor properties, show considerable potential in TNBC treatment as they can identify and eliminate tumor cells without reliance on MHC restrictions. These cells de

Совпадение в полном тексте источника
… However, the clinical response rate is typically lower compared to that observed in cases of overt metastasis ( 117 , 118 ).In the context of neoadjuvant therapy for breast cancer, combining letrozole with ZOL to expand γδT cells in vivo has demonstrated substantial patient benefits ( 119 ). … Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer . Breast . ( 2018 ) 38 : 114–19 . doi: 10.1016/j.breast.2017.12.017 29310035 120 Aggarwal R Lu J Kanji S Das M Joseph M Lustberg MB . …

Risk Factors for Medication-Related Osteonecrosis of the Jaw-A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid.

MRONJ (Medication-Related Osteonecrosis of the Jaw) is a condition observed in a subset of cancer patients who have undergone treatment with zoledronic acid in order to either prevent or treat bone metastases. The primary aim of this research was to establish the importance of risk factors in the development of medication-related osteonecrosis of the jaw in cancer patients receiving zoledronic acid therapy for bone metastases. The present study is an observational retrospective investigation conducted at two university centers, namely, Craiova and Constanța, and included cancer patients treate

Совпадение в полном тексте источника
… DOCETAXEL PEMETREXED (ALIMTA) PACLITAXEL NAVELBIN CYCLOPHOSPHAMIDE CARBOPLATIN ETOPOSID MELPHALAN (ALKERAN) GEMCITABINE (GEMZAR) DOXORUBICIN COMBINATION CHEMOTHERAPY | EC (EPIRUBICIN, CYCLOPHOSPHAMIDE) PACLITAXEL + NAVELBINE DOXORUBICIN + CYCLOPHOSPHAMIDE ENDOCRINE THERAPY | GOSERELIN (ZOLADEX) ABIRATERON LETROZOLE … TRASTUZUMAB(HERCEPTIN) OSIMERTINIB SUNITINIB (SUTENT) CABOZANTINIB COMBINATION CHEMOTHERAPY/HORMONOTHERAPY AND TARGETED MOLECULAR THERAPY | ATEZOLIZUMAB + ETOPOSID + CRB CYBORD (CYCLOPHOSPHAMIDE + BORTEZOMIB + DEXAMETHASONE) TAMOXIFEN + ABEMACICLIB + FULVESTRANT PALBOCICLIB + FULVESTRANT PALBOCICLIB + LETROZOLE …

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue.

In most clinical trials, thiazolidinediones do not show any relevant anti-cancer activity when used as mono-therapy. Clinical inefficacy contrasts ambiguous pre-clinical data either favoring anti-tumor activity or tumor promotion. However, if thiazolidinediones are combined with additional regulatory active drugs, so-called 'master modulators' of tumors, i.e., transcriptional modulators, metronomic low-dose chemotherapy, epigenetically modifying agents, protein binding pro-anakoinotic drugs, such as COX-2 inhibitors, IMiDs, etc., the results indicate clinically relevant communicative reprogram

Совпадение в полном тексте источника
… Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J. Clin. Oncol. 2006;24:3623–3628. doi: 10.1200/JCO.2005.04.5773. 74. …

Clinical outcomes of radiation therapy for transgender and gender-expansive people with cancer.

INTRODUCTION: Approximately 1.6 million people in the US identify as transgender, many of whom undergo gender-affirming medical or surgical therapies. While transgender individuals are diagnosed with cancer at similar rates as those who are cisgender, the impacts of radiation therapy on outcomes of gender-affirming care in transgender, nonbinary, and gender-expansive people with cancer are understudied. We report on the experiences and outcomes of transgender and gender-expansive patients receiving radiation therapy for cancer treatment. METHODS: This study is a multi-institutional retrospect

Совпадение в полном тексте источника
… He was initially treated with letrozole and transitioned to tamoxifen due to progression. Another trans man was diagnosed with an early-stage ER positive, PR positive, HER2 positive breast cancer and underwent bilateral mastectomy. …

Heterogeneous tissue-specific macrophages orchestrate metastatic organotropism of breast cancer: implications for promising therapeutics.

Compelling evidences have manifested that breast cancer cells prefer to metastasize to certain distant organs, including brain, lung, bone and liver. According to the canonical "seed and soil" theory, this prominent biological behavior, termed as metastatic organotropism, involves intricate interactions between breast cancer cells (the "seeds") and specific residents in the tumor microenvironment (the "soil"), initiating from pre-metastatic niche formation to metastatic outgrowth. Recently, multifaceted heterogeneity of tissue-specific macrophages (TSMs) and their roles played in organotropic

Совпадение в полном тексте источника
… Similar unsatisfactory conclusions were reached as for bosutinib (SKI-606), whose partnership with either letrozole (an AI) in postmenopausal HR + /HER2– MBC [ 157 ] or capecitabine in MBC and other advanced solid tumors [ 158 ] gave rise to limited efficacy. …

System analysis based on the T cell exhaustion‑related genes identifies CD38 as a novel therapy target for ovarian cancer.

Ovarian cancer (OV) is highly heterogeneous tumor with a very poor prognosis. Studies increasingly show that T cell exhaustion is prognostically relevant in OV. The aim of this study was to dissect the heterogeneity of T cell subclusters in OV through single cell transcriptomic analysis. The single RNA-sequencing (scRNA-seq) data of five OV patients were analyzed, and six major cell clusters were identified after threshold screening. Further clustering of T cell-associated clusters revealed four subtypes. Pathways related to oxidative phosphorylation, G2M checkpoint, JAK-STAT and MAPK signalin

Совпадение в полном тексте источника
… Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers . ESMO Open , 5 ( 5 ), e000926 . 10.1136/esmoopen-2020-000926 ; 33109627 PMC7592247 65. Zhang , Z. , Chen , L. , Chen , H. , Zhao , J. , Li , K. et al. ( 2022 ). …

Extracellular Vesicle-Associated miRNAs and Chemoresistance: A Systematic Review.

Cancer is a leading public health issue globally, and diagnosis is often associated with poor outcomes and reduced patient survival. One of the major contributors to the fatality resultant of cancer is the development of resistance to chemotherapy, known as chemoresistance. Furthermore, there are limitations in our ability to identify patients that will respond to therapy, versus patients that will develop relapse, and display limited or no response to treatment. This often leads to patients being subjected to multiple futile treatment cycles, and results in a reduction in their quality of lif

Совпадение в полном тексте источника
… Rodriguez-Martínez et al., 2019 [ 38 ] | Breast | Doxorubicin/cyclophosphamide Docetaxel, Trastuzumab, Tamoxifen, Anastrozole, Letrozole, Goserelin | Serum | miR-21, miR-105, miR-221 and miR-222 | UC | qRT-PCR | ↑ miR-21 and miR-105 in cancer patients versus healthy donors. … serum-derived exosomal miR-222 in chemotherapy response in breast cancer patients by examining breast cancer patient samples prior to neoadjuvant therapy, which included the use of several chemotherapeutic drugs, such as doxorubicin/cyclophosphamide, docetaxel, trastuzumab, tamoxifen, anastrozole, letrozole …

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review.

INTRODUCTION: Medication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone. To date, oral health preventive measures remain the most effective strategy to reduce MRONJ incidence, and, in this sense, the major goal is to diagnose, treat, and eradicate any oral diseases that could compromise oral health. The present systematic review aims to investigate the awareness of MRONJ among patients assuming BMAs. METHODS: A systematic literature sea

Совпадение в полном тексте источника
… Coleman R de Boer R Eidtmann H Llombart A Davidson N Neven P Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results . Ann Oncol . ( 2013 ) 24 ( 2 ): 398 – 405 . 10.1093/annonc/mds277 23047045 11. …

Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System.

Prior research has indicated that bisphosphonates (BPs) can improve periodontal disease because of their anti-osteoporosis properties. In vitro studies have shown that BPs induce cytotoxicity, inhibit wound healing, and thus affect periodontal disease. Denosumab and BPs have alternative indications. BP and denosumab are not known to correlate with gingival disorders. We assessed such a relationship by applying Bayesian and nonproportional analyses to data in the US FDA Adverse Event Reporting System (FAERS) database. The study analyzed BPs and denosumab-reported incidents with preferred terms

Совпадение в полном тексте источника
… calcium(60) | levothyroxine(240) | calcium(9) | anastrozole(86) | levothyroxine(9) | pamidronate(168) | cholecalciferol(53) | ibandronate(219) | alendronate(6) | capecitabine(85) | amlodipine(8) | docetaxel(140) | levothyroxine(23) | risedronate(205) | levothyroxine(5) | paclitaxel(85) | calcium(8) | letrozole …

Keyword Index for Volume 109

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… 2636 Jade Goody 1192 Jewish 777 JWA 2842 Kashmir 1367 Ki67 1859, 2792 KIT 559, 1625 Koehne's risk classification 1428 KRAS 3057, 3067 KSR1 2675 lactate dehydrogenase 2066 LAMC2 2636 laryngeal cancer 172 L-asparaginase 14 late relapse 2959 LC-MS/MS 1867 lead time 2014 lenvatinib 538 letrozole …

Tumor biomarkers for diagnosis, prognosis and targeted therapy.

Tumor biomarkers, the substances which are produced by tumors or the body's responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecu

Post-operative survival and use of systemic therapy in metastatic long-bone disease: 12 years of institutional experience.

BACKGROUND: Survival prediction in metastatic long-bone disease is essential for surgical decision-making, yet the performance of legacy prognostic models has declined in the era of immunotherapy and molecularly targeted agents. As these systemic therapies become routine, treatment patterns themselves may influence survival in ways not captured by earlier models. We, therefore, quantified preoperative systemic therapy use over the last decade and evaluated its association with postoperative overall survival in patients undergoing surgery for long-bone metastases. METHODS: We conducted a retro

Совпадение в полном тексте источника
… Overall survival with ribociclib plus letrozole in advanced breast cancer. N. Engl. J. Med. 2022;386(10):942–950. doi: 10.1056/NEJMoa2114663. 35. Ozay Z.I., Jo Y., Galarza Fortuna G., Hage Chehade C., Gebrael G., Ostrowski M., et al. …

New genomic and proteomic biomarker discovery in cancer: revolutionizing diagnosis and prognostication.

Cancer remains a major global health challenge, with substantial morbidity and mortality worldwide. Advances in genomic and proteomic biomarker discovery have transformed cancer diagnosis, prognosis, and treatment selection. The evolution from early serological markers such as carcinoembryonic antigen (CEA) and prostate-specific antigen (PSA) to modern multi-omics approaches enabled by next-generation sequencing (NGS), mass spectrometry (MS), and advanced bioinformatics has revolutionized personalized medicine and targeted therapy, leading to improved outcomes. This review highlights the histo

Совпадение в полном тексте источника
… DRUG: Cyclophosphamide NCT02206984 Endocrine Response in Women With Invasive Lobular Breast Cancer COMPLETED DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Fulvestrant NCT01478477 Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole … Cyclophosphamide NCT02206984 | Endocrine Response in Women With Invasive Lobular Breast Cancer | COMPLETED | DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Fulvestrant NCT01478477 | Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole …

Customized Marketing Strategies for Cancer Immunocyte Therapy Based on its Distinctive Attributes.

Cancer constitutes a persistent global health challenge, and immunocyte therapy has emerged as one approach in oncological care. This narrative review aimed to systematically analyze, synthesize, and critically interpret the therapeutic characteristics, advantages, market landscape, and current access barriers of cancer immunocyte therapy, based on thematic clustering and cross‑study integration of clinical evidence, market data, and industry reports. Immunocyte therapy exhibits distinctive features including personalization, long‑term immune memory, and observed efficacy in refractory maligna

Совпадение в полном тексте источника
… Drug interactions reduce therapeutic efficacy Hormone-dependent tumors Tamoxifen, Letrozole, Fulvestrant, Bicalutamide, Leuprorelin, Abiraterone Low Low High (standardized) [ 33–38 ] Targeted therapy 1. Inhibit abnormal signal pathways 2. Targeted inhibition of tumor angiogenesis 3. … Drug interactions reduce therapeutic efficacy | Hormone-dependent tumors | Tamoxifen, Letrozole, Fulvestrant, Bicalutamide, Leuprorelin, Abiraterone | Low | Low | High (standardized) | [ 33–38 ] Targeted therapy | 1. Inhibit abnormal signal pathways 2. Targeted inhibition of tumor angiogenesis 3. …